JP2005528337A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528337A5
JP2005528337A5 JP2003558463A JP2003558463A JP2005528337A5 JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5 JP 2003558463 A JP2003558463 A JP 2003558463A JP 2003558463 A JP2003558463 A JP 2003558463A JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5
Authority
JP
Japan
Prior art keywords
xaa
gly
ser
glp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003558463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528337A (ja
JP4282485B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/000001 external-priority patent/WO2003058203A2/en
Publication of JP2005528337A publication Critical patent/JP2005528337A/ja
Publication of JP2005528337A5 publication Critical patent/JP2005528337A5/ja
Application granted granted Critical
Publication of JP4282485B2 publication Critical patent/JP4282485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003558463A 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ Expired - Fee Related JP4282485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34647402P 2002-01-08 2002-01-08
US40509702P 2002-08-21 2002-08-21
PCT/US2003/000001 WO2003058203A2 (en) 2002-01-08 2003-01-03 Extended glucagon-like peptide-1 analogs

Publications (3)

Publication Number Publication Date
JP2005528337A JP2005528337A (ja) 2005-09-22
JP2005528337A5 true JP2005528337A5 (https=) 2006-02-02
JP4282485B2 JP4282485B2 (ja) 2009-06-24

Family

ID=26994870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558463A Expired - Fee Related JP4282485B2 (ja) 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ

Country Status (11)

Country Link
US (1) US7482321B2 (https=)
EP (1) EP1585959A4 (https=)
JP (1) JP4282485B2 (https=)
AR (1) AR038102A1 (https=)
AU (1) AU2003200839B2 (https=)
BR (1) BR0306706A (https=)
CA (1) CA2468700A1 (https=)
MX (1) MXPA04006679A (https=)
PE (1) PE20030820A1 (https=)
TW (1) TW200306202A (https=)
WO (1) WO2003058203A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1605897B1 (en) 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
US7538185B2 (en) 2004-01-08 2009-05-26 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
JP2008501765A (ja) * 2004-06-11 2008-01-24 ノボ ノルディスク アクティーゼルスカブ Glp−1アゴニストを用いた薬剤誘発性肥満の中和
EP1781695A1 (en) * 2004-08-18 2007-05-09 Eli Lilly And Company Selective vpac2 receptor peptide agonists
CA2603630C (en) 2005-01-14 2015-06-09 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー/エス 伸長されたglp−1化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0612471A2 (pt) * 2005-05-05 2016-09-06 Cadila Healthcare Ltd novos compostos como agonistas glp-1
PT1881850E (pt) * 2005-05-13 2010-11-26 Lilly Co Eli Compostos peguilados de glp-1
US20080194482A1 (en) * 2005-08-11 2008-08-14 Jorge Alsina-Fernandez Selective Apac2 Receptor Peptide Agonists
PL1767545T3 (pl) 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
BRPI0617740A2 (pt) 2005-10-26 2011-08-02 Lilly Co Eli agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas
ES2586236T3 (es) * 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Glp−1のポリマ複合体
CA2638733A1 (en) * 2006-02-28 2007-09-07 Eli Lilly And Company Selective vpac2 receptor peptide agonists
JP2009532422A (ja) * 2006-04-03 2009-09-10 ノボ・ノルデイスク・エー/エス Glp−1ペプチドアゴニスト
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
WO2009155257A1 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
JP2013543898A (ja) 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
US20140294977A1 (en) 2011-11-23 2014-10-02 Durect Corporation Radiation-Sterilized Biodegradable Drug Delivery Composition
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR20160021183A (ko) * 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
RS63523B1 (sr) 2018-04-05 2022-09-30 Sun Pharmaceutical Ind Ltd Novi glp-1 analozi

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
JP2002512175A (ja) * 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Glp−1類似体の誘導体類
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
CA2452044A1 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
WO2003035099A1 (en) * 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin

Similar Documents

Publication Publication Date Title
JP2005528337A5 (https=)
JP2010538049A5 (https=)
US10961287B2 (en) Extended recombinant polypeptides and compositions comprising same
JP2008533105A5 (https=)
EP3398961B1 (en) Triple activator activating glucagon, glp-1 and gip receptor
JP2014529629A5 (https=)
CN101993485B (zh) 促胰岛素分泌肽类似物同源二聚体及其用途
RU2006120079A (ru) Производные глюкагоноподобного пептида-1 (glp-1)
JP2003505347A5 (https=)
JP2001011095A5 (https=)
RU2007119990A (ru) Слитые конструкции лекарственного средства и конъюгаты
JP4227894B2 (ja) グルカゴン様ペプチド1アナログ
EP2729481B1 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2013517307A5 (https=)
RU2007134156A (ru) Ацилированные glp-1 соединения
JP2013543853A5 (https=)
EP2844269A1 (en) Transmucosal delivery of engineered polypeptides
JP2004509079A5 (https=)
TW201010729A (en) GIP-based mixed agonists for treatment of metabolic disorders and obesity
JP2002538081A (ja) Glp−1の類似体
JP2005528337A (ja) 伸長グルカゴン様ペプチド−1アナログ
JP2007519642A5 (https=)
JP2005514060A5 (https=)
PE20231842A1 (es) Coagonistas de los receptores de glp-1 y gip
JP2014501712A5 (https=)